(Q34569946)

3 August 2017

1 reference

title

Metronomic scheduling: the future of chemotherapy? (English)

1 reference

3 August 2017

1 reference

G Gasparini

1

1 reference

3 August 2017

1 December 2001

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

733-740

1 reference

3 August 2017

12

1 reference

Shifting the cancer paradigm: must we kill to cure?

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Chemotherapeutic drugs--more really is not better

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Pharmacogenetic applications of the Human Genome project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

A cancer therapy resistant to resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

The microenvironment of the tumour-host interface

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

The rationale and future potential of angiogenesis inhibitors in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Genes expressed in human tumor endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Vascular attack as a therapeutic strategy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Antiangiogenic potential of camptothecin and topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Role of interferons in the regulation of cell proliferation, differentiation, and development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Differences in vascular response between primary and transplanted tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

High-time chemotherapy or high time for low dose

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Increased dose-intensity in small-cell lung cancer: a failed strategy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Combinations for cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900587-3

7 January 2021

10.1016/S1470-2045(01)00587-3

Identifiers

DOI

1 reference

release_x56b2li2z5fklng6r54yhzaibe

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x56b2li2z5fklng6r54yhzaibe

24 November 2022

mapped directly with Wikidata item

PubMed ID

11902515

1 reference

PubMed ID

11902515